Synapse Awaits Humanitarian Approval For Diaphragm Pacing System To Treat ALS
This article was originally published in The Gray Sheet
Executive Summary
Synapse Biomedical expects FDA to issue a humanitarian device exemption within weeks allowing its NeuRX diaphragm pacing system to be marketed to treat patients with amytrophic lateral sclerosis.